Medicare’s $2,100 Drug Quietly Reshapes Prescription Costs for Investors
Medicare's out-of-pocket cap for covered prescriptions rises to $2,100 in 2026, ending the donut-hole-era for many pa...
Benchmarks provide a reference point to gauge portfolio performance and risk. This intro explains how comparing returns against a relevant benchmark clarifies decisions and helps align goals.
22,975 articlesMedicare's out-of-pocket cap for covered prescriptions rises to $2,100 in 2026, ending the donut-hole-era for many pa...
Netflix falls on growth and valuation concerns while iHeartMedia rises on an expanded podcast partnership. The move h...
OpenAI's planned IPO faces a timing change that could redefine AI stock bets. The shift underscores a tougher funding...
As the RMD age rises to 73, near-retirees with sizable pre-tax accounts are weighing Roth conversions now to reduce t...
Oracle faced a notable June pullback as its AI cloud strategy met mixed reactions. This article breaks down what happ...
Micron looks cheaper than its earnings prospects suggest, but a closer look reveals cyclicality, demand swings, and r...
In 2025, the U.S. minted 441,000 new millionaires as the median American wealth contracted, underscoring a split econ...
The price gap between gasoline and crude has widened, causing gasoline prices rising faster than oil at the pump even...
Debt worries surround a proposed $1.5 trillion boost to the Pentagon budget, drawing pushback from fiscal hawks and r...
Block announces a sweeping AI-driven layoff, cutting roughly 4,000 jobs and shrinking headcount to under 6,000. The m...
Broadcom is set to report Q1 FY2026 after the close as investors weigh AI-driven demand and margins. This live earnin...
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...